title: Development of resistance to 9-nitro-camptothecin by human leukemia U-937 cells in vitro correlates with altered sensitivities to several anticancer drugs.
abstract: We have recently reported that exposure of human leukemia U-937 cells to progressively increasing concentrations of 9-nitro-camptothecin (9NC) resulted in cell sublines exhibiting various levels of resistance to 9NC. Here, we report responses of wild-type (U-937/wt) and 9NC-resistant (U-937/CR) cells to various anticancer drugs used extensively in cancer chemotherapy. U-937/CR cells were more sensitive than U-937/wt cells to several commonly used drugs of diverse origin including the topoisomerase II-directed drugs amsacrine, etoposide and daunorubicin; the vinca alkaloid vincristine; and the antimetabolite methotrexate. No responses were induced by carmustine in either cell type, whereas similar responses were induced by cytarabine. The sensitivity to the drugs was investigated by monitoring cell proliferation, by determining cell cycle perturbations assessed by flow cytometry analysis of DNA content and by microscopy of stained cells. The results in this report indicate that development of 9NC resistance by the U-937 cells is accompanied by increased sensitivities to other anticancer drugs in vitro and very likely in vivo.
authors.affiliation: Stehlin Foundation for Cancer Research, Houston, TX 77003.
authors.forename: P
authors.initials: P
authors.lastname: Pantazis
authors.forename: J
authors.initials: J
authors.lastname: Mendoza
authors.forename: A
authors.initials: A
authors.lastname: DeJesus
authors.forename: J
authors.initials: J
authors.lastname: Early
authors.forename: M
authors.initials: M
authors.lastname: Shaw
authors.forename: B C
authors.initials: BC
authors.lastname: Giovanella
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000494:pharmacology; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D004250:DNA Topoisomerases, Type II / Q000187:drug effects; D004273:DNA, Neoplasm / Q000032:analysis; D018432:Drug Resistance, Multiple; D004354:Drug Screening Assays, Antitumor; D005434:Flow Cytometry; D006801:Humans; D007942:Leukemia, Experimental / Q000188:drug therapy* / Q000473:pathology; D008853:Microscopy; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D004250:DNA Topoisomerases, Type II; C079905:rubitecan; D002166:Camptothecin